Bárbara Gomes

Bárbara Gomes

Auto-generated profile, based on publicly available information

Bárbara Gomes

Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa, Av. Prof. Egas Moniz, 1649-028 Lisbon, Portugal

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2018 in Biotechnology Advances
Verified
Journal Article
Closed access
BGBárbara Gomes
Bárbara Gomes
MAMarcelo T. Augusto
Marcelo T. Augusto
MFMário Felício
Mário Felício
AHAxel Hollmann
Axel Hollmann
Octavio FrancoOctavio Franco
Octavio Franco
Nuno SantosNuno Santos
Nuno Santos

1 September 2016 in Colloids and Surfaces B: Biointerfaces
Verified
Journal Article
Closed access
Joana LoureiroJoana Loureiro
Joana Loureiro
BGBárbara Gomes
Bárbara Gomes
Gert FrickerGert Fricker
Gert Fricker
MCManuel A.N. Coelho
Manuel A.N. Coelho
SRSandra Rocha
Sandra Rocha
Maria de Lourdes PereiraMaria de Lourdes Pereira
Maria de Lourdes Pereira

1 April 2014 in Nanomedicine
Verified
Journal Article
Closed access
Joana LoureiroJoana Loureiro
Joana Loureiro
BGBárbara Gomes
Bárbara Gomes
MCManuel A.N. Coelho
Manuel A.N. Coelho
Maria de Lourdes PereiraMaria de Lourdes Pereira
Maria de Lourdes Pereira
SRSandra Rocha
Sandra Rocha
Development of therapeutics for brain disorders is one of the more difficult challenges to be overcome by the scientific community due to the inability of most molecules to cross the blood-brain barrier (BBB). Antibody-conjugated nanoparticles are drug carriers that can be used to target encapsulated drugs to the brain endothelial cells and have proven to be very promising. They significantly improve the accumulation of the drug in pathological sites and decrease the undesirable side effect of drugs in healthy tissues. We review the systems that have demonstrated promising results in crossing the BBB through receptor-mediated endocytic mechanisms for the treatment of neurodegenerative disorders such as Alzheimer's and Parkinson's disease.

1 October 2015 in Colloids and Surfaces B: Biointerfaces
Verified
Journal Article
Closed access
Joana LoureiroJoana Loureiro
Joana Loureiro
BGBárbara Gomes
Bárbara Gomes
Gert FrickerGert Fricker
Gert Fricker
ICIsabel Cardoso
Isabel Cardoso
CRCarlos A Ribeiro
Carlos A Ribeiro
SRSandra Rocha
Sandra Rocha

12 June 2015 in Beilstein Journal of Nanotechnology
Verified
Journal Article
Open access
PDF file
Maria João RamalhoMaria João Ramalho
Maria João Ramalho
Joana LoureiroJoana Loureiro
Joana Loureiro
BGBárbara Gomes
Bárbara Gomes
MFManuela Faria Frasco
Manuela Faria Frasco
MCManuel A.N. Coelho
Manuel A.N. Coelho
Maria de Lourdes PereiraMaria de Lourdes Pereira
Maria de Lourdes Pereira
Poly(lactic-co-glycolic acid) (PLGA) nanoparticles were studied as drug delivery vehicles for calcitriol, the active form of vitamin D3. In vitro effects of calcitriol encapsulated in PLGA nanoparticles were evaluated with respect to free calcitriol on human pancreatic cell lines, S2-013 and hTERT-HPNE, and the lung cancer cell line A549. Encapsulated calcitriol retained its biological activity, reducing the cell growth. Cytotoxicity assays demonstrated that encapsulation of calcitriol enhanced its inhibitory effect on cell growth at a concentration of 2.4 μM for the S2-013 cells (91%) and for A549 cells (70%) comparared to the free calcitriol results. At this concentration the inhibitory effect on nontumor cells (hTERT-HPNE) decreased to 65%. This study highlights the ability of PLGA nanoparticles to deliver vitamin D3 into cancer cells, with major effects regarding cancer cell cycle arrest and major changes in the cell morphological features.

1 May 2018 in Biochimica et Biophysica Acta (BBA) - Biomembranes
Verified
Journal Article
Closed access
BGBárbara Gomes
Bárbara Gomes
SGSónia Gonçalves
Sónia Gonçalves
ADAnibal Disalvo
Anibal Disalvo
AHAxel Hollmann
Axel Hollmann
Nuno SantosNuno Santos
Nuno Santos